Background and Objectives: To compare uterine leiomyosarcomas (LMS) and leiomyomas (LM) with normal myometrium in terms of microvessel density (MVD), and to correlate this parameter with vascular endothelial growth factor (VEGF) expression and clinical/pathological parameters. Methods: An immunohistochemical technique, using antibodies against von Willebrand factor (FvW), CD34, CD31, and VEGF, was applied to formalin-fixed paraffin-embedded samples of 32 normal myometria, 32 uterine LM, and 12 LMS. MVD was calculated by a digital image analyzer. Results: Using anti-FvW, mean ± SD MVD in myometrium, LM, and LMS was 107.0 ± 53.6, 66.2 ± 55.4, and 64.4 ± 44.2, respectively (P = 0.001). MVD was lower in LMS (P = 0.021) and in LM (P = 0.0004) than in normal myometrium. Using anti-CD34, mean ± SD MVD in myometrium, LM, and LMS was 187.6 ± 91.2, 106.1 ± 55.5, and 114.2 ± 98.8, respectively (P = 0.001). MVD was lower in LMS (P = 0.012) and LM (P = 0.0004) than in normal myometrium. No such differences were found using anti-CD31 and anti-VEGF. No correlation was found between MVD and VEGF expression. In women with uterine LMS, low MVD (assessed with anti-FvW) correlated with recurrence (P = 0.04) and poor overall survival (P = 0.03). Conclusions: Uterine smooth muscle tumors exhibit a lower MVD than normal myometrium, as assessed using anti-FvW or anti-CD34 antibodies. A reduced MVD, as assessed by FvW staining, has prognostic value in uterine LMS. © 2004 Wiley-Liss, Inc.
CITATION STYLE
Poncelet, C., Fauvet, R., Feldmann, G., Walker, F., Madelenat, P., & Darai, E. (2004). Prognostic Value of von Willebrand Factor, CD34, CD31, and Vascular Endothelial Growth Factor Expression in Women with Uterine Leiomyosarcomas. Journal of Surgical Oncology, 86(2), 84–90. https://doi.org/10.1002/jso.20055
Mendeley helps you to discover research relevant for your work.